Diabetes is the fourth or fifth leading cause of death in most developed countries. More than 90 percent of the diabetes patients have type 2 diabetes.

An Epidemic
The incidence of type 2 diabetes is increasing rapidly in the western world as well as in the developing countries. The market for anti-diabetes drugs is substantial with annual sales in the order of USD 15 billion. Oral medicines are first line treatment but as the disease progresses most patients will have to inject insulin to control blood sugar levels.

Karo Bio’s KB3305 is a new liver selective compound for treatment of type 2 diabetes, with the purpose to control blood sugar production in the liver. The mainstay oral treatment today is metformin. However, prolonged treatment with metformin often shows inadequate effect. KB3305 will likely be given as an add on agent to metformin before introduction of injectable insulin.